NCIt definition : An orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian
target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential
antineoplastic activity. Apitolisib inhibits both PI3K kinase and mTOR kinase, which
may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing
PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and
resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream
of PI3K, may also be activated in a PI3K-independent fashion.;
UNII : 1C854K1MIJ;
InChIKey : YOVVNQKCSKSHKT-HNNXBMFYSA-N;
CAS number : 1032754-93-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1032754-93-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : GDC-0980; GDC 0980; GNE 390; RG 7422;
See also inter- (CISMeF)